Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ dystonia ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus TAC: sequelae ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.09 [0.01, 1.45]
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ fractional CO2 laser versus verapamil ‐ charring ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐… compared with other treatments (very low certainty).
1 finding from 1 review
RR 7
Studies not reported
Very low
Adverse effects associated with wearing the device (such as pain, discomfort, tenderness or skin irritation, or ear infections) · adults with subjective idiopathic tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects associated with wearing the device (such as pain, discomfort, tenderness or skin irritation, or ear infections) · adults with tinnitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · psychosis‐induced aggression or agitation
Benzodiazepines + antipsychotics showed no clear difference in adverse effects/events: extrapyramidal symptoms ‐ +/vs haloperidol ‐… compared with same antipsychotics (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (medium term) · patients with schizophrenia
It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus 5‐FU ‐ purpura ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with other treatments (very low certainty).
1 finding from 1 review
RR 4.2
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ hyperpigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 5
Studies not reported
Very low
Withdrawals due to adverse events · patients with Raynaud's phenomenon
Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects (tooth staining/discoloration, oral soft-tissue signs, adverse symptoms such as nausea/vomiting, enamel etching) · Children and adolescents aged 16 years or less
1 finding from 1 review
Data on adverse effects (stain score, proportion of children with tooth staining, signs of sensitivity in oral soft tissue, adverse symptoms such as nausea/vomiting, etching of enamel) were reported in only a few…
Studies not reported
GRADE not reported
Incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC versus cryosurgery plus TAC ‐ telangiectasia ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC… compared with other treatment (very low certainty).
1 finding from 1 review
RR 0.33 [0.07, 1.52]
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ NAFL versus no treatment ‐ hyperpigmentation ‐ hypertrophic scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ NAFL… compared with no treatment (very low certainty).
1 finding from 1 review
RR 3
Studies not reported
Very low
Adverse effects: extrapyramidal adverse effects Parkinsonism medium term (3‐12 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
1 finding from 1 review
Incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC versus cryosurgery plus TAC ‐ hypopigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC… compared with other treatment (very low certainty).
1 finding from 1 review
RR 0.6 [0.16, 2.29]
Studies not reported
Very low
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Serious adverse events Number of participants who died or withdrew and were hospitalized as a result of adverse effects of treatment · patients with Raynaud's phenomenon
1 finding from 1 review
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Incidence and severity of treatment‐related adverse effects ‐ 585‐nm PDL versus no treatment ‐ purpura ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐ 585‐nm… compared with no treatment (very low certainty).
1 finding from 1 review
RR 21.32
Studies not reported
Very low